Evidence map›Paper›PMID 41612407›Full record

ArticleBMC chemistry2026

Synthesis, QSAR analysis and molecular docking study of a new series of 3-hydroxypyridine-4-one derivatives as anti-tyrosinase agents.

Hossein Sadeghpour, Sara Sadeghian, Leila Emami, Mehdi Khoshneviszadeh, Paria Razmi, Zahra Karimi Ghezeli, Alireza Moradian, Alireza Bahrampour, Razieh Sabet

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hossein SadeghpourDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara SadeghianDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila EmamiPharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi KhoshneviszadehDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Paria RazmiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra Karimi GhezeliDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza MoradianDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza BahrampourDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Razieh SabetDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. sabet_r@sums.ac.ir.

Funding

Shiraz University of Medical Sciences 26571 and 25951
6 · The paper itself

Abstract

Tyrosinase is a critical rate-limiting enzyme in the melanogenesis pathway. Consequently, its inhibition represents a rational therapeutic strategy for treating skin disorders associated with excessive melanin production. In the present study, a series of novel 3-hydroxypyridine-4-one derivatives (6a-i) were synthesized, and their chemical structures were confirmed using spectroscopic techniques. The inhibitory potency of these compounds against tyrosinase was predicted using quantitative structure-activity relationship (QSAR) analysis. QSAR modeling was conducted on twenty-four previously synthesized 3-hydroxypyridin-4-one derivatives with established anti-tyrosinase activity. The best-performing model was subsequently employed to predict the IC

Indexed as

3-Hydroxypyridine-4-oneMolecular docking.QSARSynthesisTyrosinase

Identifiers

PMID41612407
PMCPMC12924469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.